

Sierra Oncology Inc.

Fact Sheet

S R R A

L I S T E D

N A S D A Q

SIERRA ONCOLOGY

QUICK REFERENCE

Sierra Oncology Inc.
Nasdaq: **SRRA**

Website: www.SIERRAONCOLOGY.com

BUSINESS SUMMARY

Sierra Oncology is a late-stage biopharmaceutical company on a mission to deliver targeted therapies that treat rare forms of cancer. We harness our deep scientific expertise to identify compounds that target the root cause of disease, advancing therapies on the leading edge of cancer biology. Our team takes an evidence-based approach to understand the limitations of current treatments and explore new ways to change the cancer treatment paradigm.

Our lead product candidate, momelotinib, is a selective and orally bioavailable JAK1, JAK2 and ACVR1/ALK2 inhibitor currently under investigation for the treatment of myelofibrosis. Myelofibrosis results from dysregulated JAK-STAT signaling and is characterized by constitutional symptoms, an enlarged spleen and progressive anemia. Topline data from the MOMENTUM clinical trial—a global, randomized, double-blind Phase 3 study for symptomatic and anemic myelofibrosis patients—were announced in January 2022. The US Food & Drug Administration has granted Fast Track designation for momelotinib.

In August 2021 we in-licensed SRA515 (formerly AZD5153), a selective BRD4 BET inhibitor with a novel bivalent binding mode that inhibits both protein bromodomains. Preclinical and early clinical data suggest SRA515 is a differentiated BET inhibitor through its high potency, selectivity, and bivalent binding, which may offer more complete target inhibition relative to monovalent binders. Initiation of a Phase 2 clinical trial evaluating the combination of momelotinib and SRA515 is planned for the first half of 2022. The trial will be designed to provide preliminary proof of concept for a future confirmatory study and support potential additional studies of momelotinib with other novel agents in development for myelofibrosis.

DISEASE FOCUS

Myelofibrosis (MF) is a rare blood cancer that progressively impairs red blood cell production. It is thought to be driven by dysregulation of the JAK-STAT pathway.¹ Continual activation of this pathway results in local inflammation and progressive bone marrow fibrosis, reducing the hematopoietic capacity of the marrow (anemia) and triggering extramedullary hematopoiesis in the spleen (splenomegaly).² The systemic pro-inflammatory cytokine profile (eg IL-6) induces a hyper-metabolic state and constitutional symptoms³ and drives production of hepcidin, the master regulator of iron homeostasis. Elevated hepcidin restricts iron availability for erythropoiesis, further reducing red blood cell.

CONTACT INFORMATION

Headquarters
1820 Gateway Drive
San Mateo, CA 94404

Investor Relations Contact
Andrew Barwicki
516-662-9461/andrew@barwicki.com

Recent Press Releases *(Headlines and Excerpts)*

Sierra Oncology Announces Full Exercise of Underwriters' Option to Purchase Additional Shares

02/03/2022 -- Sierra Oncology, Inc. announced that the underwriters of its previously announced underwritten public offering exercised in full their option to purchase 750,000 additional shares of common stock at a price of \$27.00 per share, before deducting underwriting discounts and commissions. With this exercise, the aggregate gross proceeds to Sierra Oncology from the offering were approximately \$155.3 million, before deducting underwriting discounts and commissions and other offering expenses. The offering of the additional 750,000 shares closed on February 3, 2022. Sierra Oncology intends to use the net proceeds of the offering to prepare for potential commercialization of momelotinib, clinical development of its other product candidates, research, clinical and process development and manufacturing of its product candidates, working capital, and capital expenditures and other general corporate purposes.

Jefferies and Cantor acted as the joint book-running managers and representatives of the underwriters for the offering. LifeSci Capital, Oppenheimer & Co. and H.C. Wainwright & Co. acted as lead managers for the offering.

Sierra Oncology to Participate in Guggenheim Oncology Conference

02/03/2022 -- Sierra Oncology, Inc. announced the company will participate in the 4th Annual Guggenheim Oncology Conference being held virtually from February 9 – 11, 2022. President and Chief Executive Officer Stephen Dilly, MBBS, PhD, will participate in an analyst-moderated fireside chat on Thursday, February 10, 2022, at 12:00 pm ET.

A replay of the presentation will be available following the conference on the Investors section of Sierra's corporate website in the Events & Webcast tab. The replay will be available for approximately 30 days following the presentation.

Sierra Oncology Announces Closing of Upsized Public Offering of \$135.0 Million of Securities

01/31/2022 -- Sierra Oncology, Inc. announced the closing of its previously announced underwritten public offering of 4,074,075 shares of its common stock at a price to the public of \$27.00 per share and, in lieu of shares of common stock, to a certain investor, pre-funded warrants to purchase up to 925,925 shares of common stock at a price to the public of \$26.999 per pre-funded warrant, which represents the per share public offering price for the common stock less the \$0.001 per share exercise price for each pre-funded warrant. The gross proceeds to Sierra Oncology from the offering were approximately \$135.0 million, before deducting underwriting discounts and commissions and other offering expenses. Net proceeds to Sierra Oncology from the offering were approximately \$126.6 million after deducting underwriting discounts and commissions and other offering expenses. Sierra Oncology intends to use the net proceeds of the offering to prepare for potential commercialization of momelotinib, clinical development of its other product candidates, research, clinical and process development and manufacturing of its product candidates, working capital, and capital expenditures and other general corporate purposes.

Jefferies and Cantor are acting as the joint book-running managers and representatives of the underwriters for the offering. LifeSci Capital, Oppenheimer & Co. and H.C. Wainwright & Co. are acting as lead managers for the offering.

Sierra Oncology Provides Financial Update to Support the Future Commercialization of Momelotinib

- ***Oxford Finance Debt Facility for up to \$125 Million***
- ***Series B Warrants Will Expire in 75 Days, and if Fully Exercised, Could Provide An Additional \$33.3 Million***

01/25/2022 -- Sierra Oncology, Inc. announced it has entered into a term loan agreement with Oxford Finance, LLC that is designed to primarily support the commercial preparation and potential launch of momelotinib, an investigational agent for the treatment of myelofibrosis, a rare form of blood cancer. The Company estimates it had cash and cash equivalents of \$104.7 million as of December 31, 2021.

Standard Mail
U.S. Postage Paid
Garden City, NY
Permit No. 431

Sierra Oncology Inc.

Nasdaq: SRRRA

www.SIERRAONCOLOGY.COM

Barwicki Investor Relations • 30 Wall Street, 8 FL • New York, NY 10005

Deliver to: